These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33021700)

  • 1. Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden.
    Bernfort L; Husberg M; Wiréhn AB; Rosenqvist U; Gustavsson S; Karlsdotter K; Levin LÅ
    Diabetes Ther; 2020 Dec; 11(12):2921-2930. PubMed ID: 33021700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.
    Fitchett DH
    Eur Endocrinol; 2018 Sep; 14(2):40-49. PubMed ID: 30349593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
    Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
    Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study.
    Bernfort L; Husberg M; Wiréhn AB; Rosenqvist U; Gustavsson S; Karlsdotter K; Levin LÅ
    Diabetes Ther; 2020 Jul; 11(7):1537-1549. PubMed ID: 32468515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
    Gallwitz B
    Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease.
    Ehlers LH; Lamotte M; Monteiro S; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
    Diabetes Ther; 2021 May; 12(5):1523-1534. PubMed ID: 33856655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
    Nguyen E; Coleman CI; Nair S; Weeda ER
    J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease.
    Ramos M; Foos V; Ustyugova A; Hau N; Gandhi P; Lamotte M
    Diabetes Ther; 2019 Dec; 10(6):2153-2167. PubMed ID: 31602601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Marx N; McGuire DK
    Eur Heart J; 2016 Nov; 37(42):3192-3200. PubMed ID: 27153861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
    Arbel R; Hammerman A; Azuri J
    Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
    Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
    ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
    Cavaiola TS; Pettus J
    Diabetes Metab Syndr Obes; 2018; 11():133-148. PubMed ID: 29695924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey.
    Eliasson B; Ekelund J; Amberntsson R; Miftaraj M; Svensson AM
    Diabetes Ther; 2019 Aug; 10(4):1523-1530. PubMed ID: 31089969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.